PHARMALUNDENSIS AB
NNGM:PHAL0.32
SEK
-0.04
(-11.70%)
ISIN
SE0003359710
Return %
Stock
S&P 500
1Y
-9.43
14.20
3Y
2.94
81.12
5Y
-53.78
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Staffan Skogvall
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Lund Sweden
- Website
- pharmalundensis.se
- Similar Companies
- Business
- PharmaLundensis AB is a Swedish biotechnology and clean technology company that develops pharmaceutical treatments, medical technologies, and environmental filtration systems for chronic respiratory illnesses and heavy metal abatement. Founded in 2007 and headquartered in Lund, Sweden, the company focuses on advancing specialized therapeutic candidates and industrial purification equipment primarily serving healthcare, clinical, and environmental management sectors across the Nordic region and broader Europe. PharmaLundensis AB operates across two main operational segments: Biopharmaceuticals and Environmental Technology. The company's core product and technology portfolio comprises: iodinated activated carbon (IGM) therapeutic substances engineered to reduce bacterial load, clear excessive mucus secretions, and improve respiratory airflow for patients with Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis; oral heavy metal-binding clinical candidates targeted at reducing systemic heavy metal toxicity in chronic fatigue and post-viral indications; the Eco-Filter system, an advanced multi-stage mercury filtration apparatus designed to extract volatile mercury vapors and toxic emissions from dental practices, hospitals, crematoria, and industrial facilities; and diagnostic pulmonary function testing systems. In recent developments, PharmaLundensis AB has executed a strategic expansion to prioritize commercial rollouts of its Eco-Filter technology across European markets to meet heightened regulatory standards for mercury emission controls. The company has completed rights offerings to finance manufacturing scale-up, regulatory compliance pathways, and clinical trial milestones. Additionally, PharmaLundensis has broadened the therapeutic evaluation of its proprietary IGM platform toward long-term post-viral respiratory complications and entered into strategic commercial distribution and testing agreements with industrial and environmental service partners.